Clinical activity at the time of US examination was assessed using the HBI (clinical remission, HBI ≤ 4; mild disease activity, 5 ≤ HBI ≤ 7; moderate–severe disease activity, HBI ≥ 8) while CRP was used as the biochemical activity marker (positive if > 0.8 mg/dl). For statistical analysis, patients were dichotomized in mild (HBI ≤ 7) and moderate–severe activity (HBI ≥ 8).
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.